Floctafenine

Identification

Summary

Floctafenine is an anti-inflammatory analgesic used to manage mild to moderate acute pain.

Generic Name
Floctafenine
DrugBank Accession Number
DB08976
Background

Floctafenine is an anti-inflammatory analgesic similar in action to aspirin. Floctafenine inhibits prostaglandin synthesis.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
Weight
Average: 406.3552
Monoisotopic: 406.114041657
Chemical Formula
C20H17F3N2O4
Synonyms
  • Floctafenina
  • Floctafenine
  • Floctafeninum
External IDs
  • R 4318
  • R-4138
  • R-4318
  • RU 15750

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofMild acute pain••••••••••••
Management ofModerate acute pain••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirFloctafenine may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Abciximab.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Floctafenine.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Floctafenine.
AcemetacinThe risk or severity of adverse effects can be increased when Floctafenine is combined with Acemetacin.
Food Interactions
  • Avoid alcohol. Consuming alcohol increases the risk of gastrointestinal irritation.
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Herbs with anticoagulant effects may increase the risk of gastrointestinal bleeding. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
  • Take after a meal. Food reduces gastric irritation.
  • Take with a full glass of water.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Diralgan / Idalon / Novodolan
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
FloctafenineTablet400 mgOralAa Pharma Inc2001-11-14Not applicableCanada flag
FloctafenineTablet200 mgOralAa Pharma Inc2001-11-14Not applicableCanada flag
IdaracTablet200 mgOralSanofi Synthelabo1985-12-312004-08-05Canada flag
IdaracTablet400 mgOralSanofi Synthelabo1988-12-312004-08-05Canada flag

Categories

ATC Codes
N02BG04 — Floctafenine
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
O04HVX6A9Q
CAS number
23779-99-9
InChI Key
APQPGQGAWABJLN-UHFFFAOYSA-N
InChI
InChI=1S/C20H17F3N2O4/c21-20(22,23)15-6-3-5-13-17(8-9-24-18(13)15)25-16-7-2-1-4-14(16)19(28)29-11-12(27)10-26/h1-9,12,26-27H,10-11H2,(H,24,25)
IUPAC Name
2,3-dihydroxypropyl 2-{[8-(trifluoromethyl)quinolin-4-yl]amino}benzoate
SMILES
OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C=CC=C12)C(F)(F)F

References

Synthesis Reference

U.S. Patent 3,644,368.

General References
Not Available
PubChem Compound
76958517
PubChem Substance
310264938
ChemSpider
3243
RxNav
4444
ChEBI
31612
ChEMBL
CHEMBL2105075
Wikipedia
Floctafenine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral200 mg
TabletOral400 mg
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)179-180U.S. Patent 3,644,368.
Predicted Properties
PropertyValueSource
Water Solubility0.0346 mg/mLALOGPS
logP3.05ALOGPS
logP4.43Chemaxon
logS-4.1ALOGPS
pKa (Strongest Acidic)13.62Chemaxon
pKa (Strongest Basic)5.84Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area91.68 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity98.72 m3·mol-1Chemaxon
Polarizability37.76 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0009000000-16ea1f7ceba4e5de6a79
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001u-7059000000-50e219356b6b8157ee4e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0009000000-c04328bf9f15c7a71717
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03ei-1059000000-d5819f127dfb2ec055fb
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0091000000-02c083b25c65d5fa8022
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-014j-0089000000-fd1b7c0631c2988a8339
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-186.40678
predicted
DeepCCS 1.0 (2019)
[M+H]+188.76479
predicted
DeepCCS 1.0 (2019)
[M+Na]+195.80959
predicted
DeepCCS 1.0 (2019)

Drug created at June 09, 2014 20:37 / Updated at February 20, 2024 23:55